Wednesday, October 24, 2012
An estimated 14,000 people in the US are at risk for having contracted meningitis for having a steroid injection that has caused a nationwide outbreak from contaminated mixed drugs, called methylprednisolone, manufactured by New England Compounding Center (NECC). A total of 17,000 vials have been shipped to 23 states.
Reported by mainstream propaganda, the recorded meningitis cases have been caused by the fungus Exserohilum, a type of black mold. Exserohilum can cause skin and sinus infections, inflammation of the lining of the heart, and bone infections. It also weakens the human immune system which can cause other infections. Treatment includes intravenous doses of voriconazole, a severe antifungal drug which causes liver and kidney complications, as well as hallucinations and irregular heart rhythms.
report claiming no new deaths due to meningitis. The CDC has reported that 23 people have died. Two hundred and ninty-four cases of infection have been reported in 16 states.
Ameridose, a subsidiary of the NECC has shut down due to the meningitis outbreak. An inspection of the facility is being conducted to determine the extent of the contamination. According to the Food and Drug Administration, “the current production shutdown of Ameridose may impact supplies of certain drugs for some health care systems.”
The meningitis outbreak across the nation downplays the fact that this is actually an outbreak of acute flaccid paralysis (AFP) or polio. When an individual becomes infected with the polio virus, they can develop different versions of the virus which include asceptic meningitis. Meningitis has become a new reference for polio which has been surfacing across the globe and downplaying the extent of the contamination. According to the Food and Drug Administration, “the current production shutdown of Ameridose may impact supplies of certain drugs for some health care systems.”
While the World Health Organization (WHO) back in April, the Bill and Melinda Gates Foundation (BMGF) travelled to India to administer polio vaccines which resulted in an outbreak of non-polio paralysis. Grants provided to the Indian government from BMGF and WHO funded the vaccination program.
Dr. Neetu Vashisht and Dr. Jacob Puliyel of the Department of Pediatrics at St Stephens Hospital in Delhi, India reported that after extensive lab synthesis of the polio strain in 2002, the polio virus has returned in a weaponized form that is proving impossible to eradicate.
The BMGF has poured millions of dollars into supporting Global Alliance for Vaccines and Immunizations (GAVI), a UN agency that also works in conjuction with WHO to administer vaccines to under-developed nations.
WHO and GAVI teamed up with the World Bank and UN Population Fund in the 1970′s under the Task Force on Vaccines for Fertility Regulation. The Task Force, “…acts as a global coordinating body for anti-fertility vaccine R&D.” GAVI is heavily funded by the Bill & Melinda Gates Foundation for the global vaccination projects. WHO hope to coerce polio-free countries to donate money. They also suggest that officials from polio-free countries have officials at airports to administer vaccinations to people at arriving from affected nations.
Back in June of this year, the FDA approved GlaxoSmithKline’s (GSK) new meningitis vaccine, MenHirix, (MHV) to be administered to infants between the ages of 6 weeks and 18 months. This drug was to be manufactured at the Belgium-based arm of GSK Biologicals.
The history of this vaccine includes the FDA’s rejection of MHV due to GSK’s lack of evidence for the necessity of it; as well as its potency and efficiency. Since the FDA relies solely on the data provided to them from the drug makers for study conclusions without conducting independent study of the accuracy of the data, GSK was able to have their vaccine approved.
In conjunction with the GSK vaccine, the CDC released propaganda urging parents to subject their children to the vaccine, claiming it would protect against the infection’s ability to attack the thin lining surrounding the brain and spinal cord.
Karen Midthum, director of the center for biologics at the FDA stated that “with today’s approval of Menhibrix, there is now a combination vaccine that can be used to prevent potentially life-threatening Hib disease and two types of meningococcal disease in children. It is the first meningococcal vaccine that can be given starting as young as six weeks of age.”
Dr. Leo Friedland, vice president of clinical and medical affairs at GSK North American division says: “(Meningitis) is one of those diseases that although not common, when it occurs it’s absolutely devastating and horrible. It presents to the doctor when a child just looks ill, and within 18 to 24 hours, they’re on the deathbed in the hospital. . . To be able to have a vaccine to prevent meningitis is really a great day.”
- The MHV targets only the C and Y strains of meningococcal bacteria and the Hib bacteria (a.k.a. Haemophilus influenzae type b).
- GSK says there is no vaccine in the US to treat the B strain of the meningococcal bacteria.
- GSK is planning on administering 1.1 billion doses of MHV to 173 countries in developed and developing countries.
- GSK maintains that MHV was evaluated on 7,500 infants and toddlers in the U.S., Mexico and Austria.